Spots Global Cancer Trial Database for CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

Official Title: CD19-targeting CAR T Cell Therapy in the Treatment of Relapsed or Refractory CD19 Positive B-cell Malignancies

Study ID: NCT03559439

Conditions

B-cell Malignancy

B-cell Lymphoma

B-Cell Acute Lymphoblastic Leukaemia

Interventions

CD19 CAR T

Study Description

Brief Summary: This is a single center, single arm, open-label phase 1 study to determine the safety and efficacy of autologous T cells expressing CD19 chimeric antigen receptors in adults with CD19+ B cell malignancies.

Detailed Description: This is a single-center, Open Label phase I clinical trial, 9 subjects planned to be enrolled. The subjects will be divided into low-dose group, medium-dose group and high-dose group.Dose CAR+ cells/kg Low 1×105 Medium 2×106 High 6×106